Henlius Seeks To Add RA Indication To Chinese Rituximab
HLX01 Biosimilar Was First Approved In China Under New Pathway
• By David Wallace
Henlius is seeking to add the rheumatoid arthritis indication to its rituximab biosimilar • Source: Shutterstock 
